News

Abbott acquired the license agreement between Jerini US and Kos Life Sciences as part of the company's takeover of Kos Pharmaceuticals. After an in-depth review following the Kos

The submission is supported in part by data from a study that demonstrated the efficacy of Erbitux as a first-line treatment in metastatic colorectal cancer (mCRC) patients. The

The technical board of appeal of the European patent office (EPO) has affirmed the decision to revoke the claims of European patent 1093381 as granted to Pharmexa in

MEP Chris Heaton-Harris has asked the Commission to look into UK drug distribution on the grounds that it breaks European anti-discrimination laws. Mr Heaton-Harris is defending a patient

The company also announced a median one-year survival rate of 17.6% in the Phase II population of mostly platinum-refractory and -resistant patients studied in this trial. Picoplatin, the

This approval represents the first regulatory approval for Celgene in Switzerland, and Revlimid represents the first oral therapy in Switzerland for multiple myeloma patients in more than 40

This sNDA includes the removal of a dosing recommendation, which limited Aloxi use to once per seven day interval, from the product's label. Data from several safety and

The glucagon receptor (GCGR) binds glucagon, a hormone that opposes the action of insulin. The Phase I trial of ISIS 325568 is designed to assess the drug's activity,

Diastolic heart failure(DHF) is a type of congestive heart failure (CHF). “We are pleased with the clinical progress of this additional indication for sitaxsentan,” said George Cole, president